209 related articles for article (PubMed ID: 36627278)
21. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
[No Abstract] [Full Text] [Related]
22. Nanog maintains stemness of Lkb1-deficient lung adenocarcinoma and prevents gastric differentiation.
Tong X; Chen Y; Zhu X; Ye Y; Xue Y; Wang R; Gao Y; Zhang W; Gao W; Xiao L; Chen H; Zhang P; Ji H
EMBO Mol Med; 2021 Mar; 13(3):e12627. PubMed ID: 33439550
[TBL] [Abstract][Full Text] [Related]
23. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
[TBL] [Abstract][Full Text] [Related]
24. Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.
Wang X; Praça MSL; Wendel JRH; Emerson RE; DeMayo FJ; Lydon JP; Hawkins SM
Am J Pathol; 2021 Jul; 191(7):1281-1291. PubMed ID: 33882289
[TBL] [Abstract][Full Text] [Related]
25. Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.
Nagaraj AS; Lahtela J; Hemmes A; Pellinen T; Blom S; Devlin JR; Salmenkivi K; Kallioniemi O; Mäyränpää MI; Närhi K; Verschuren EW
Cell Rep; 2017 Jan; 18(3):673-684. PubMed ID: 28099846
[TBL] [Abstract][Full Text] [Related]
26. USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity.
Kwon J; Zhang J; Mok B; Allsup S; Kim C; Toretsky J; Han C
Mol Cancer; 2023 Dec; 22(1):204. PubMed ID: 38093367
[TBL] [Abstract][Full Text] [Related]
27. Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma.
Hou S; Zhou S; Qin Z; Yang L; Han X; Yao S; Ji H
Am J Pathol; 2017 May; 187(5):954-962. PubMed ID: 28284717
[TBL] [Abstract][Full Text] [Related]
28.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
29. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
[TBL] [Abstract][Full Text] [Related]
31. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.
Momcilovic M; McMickle R; Abt E; Seki A; Simko SA; Magyar C; Stout DB; Fishbein MC; Walser TC; Dubinett SM; Shackelford DB
Cancer Res; 2015 Nov; 75(22):4910-22. PubMed ID: 26574479
[TBL] [Abstract][Full Text] [Related]
32. The tumor suppressor LKB1 antagonizes WNT signaling pathway through modulating GSK3β activity in cell growth of esophageal carcinoma.
Liu K; Luo Y; Tian H; Yu KZ; He JX; Shen WY
Tumour Biol; 2014 Feb; 35(2):995-1002. PubMed ID: 24022664
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.
Bi Y; Jiang Y; Li X; Hou G; Li K
J Cancer Res Clin Oncol; 2021 Feb; 147(2):499-505. PubMed ID: 33225417
[TBL] [Abstract][Full Text] [Related]
34. S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells.
Wang R; Li Y; Hu E; Kong F; Wang J; Liu J; Shao Q; Hao Y; He D; Xiao X
Oncotarget; 2017 Apr; 8(15):24804-24814. PubMed ID: 28177901
[TBL] [Abstract][Full Text] [Related]
35. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ
Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855
[TBL] [Abstract][Full Text] [Related]
36. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
37. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress.
Inge LJ; Friel JM; Richer AL; Fowler AJ; Whitsett T; Smith MA; Tran NL; Bremner RM
Cancer Lett; 2014 Oct; 352(2):187-95. PubMed ID: 25011082
[TBL] [Abstract][Full Text] [Related]
38. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Strazisar M; Mlakar V; Rott T; Glavac D
Cancer Invest; 2009 May; 27(4):407-16. PubMed ID: 19229701
[TBL] [Abstract][Full Text] [Related]
39. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
40. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
